Observational Study of Spatio-Temporal Patterns of New Cases of Acute Myeloid Leukemia
NCT03433521 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 15000
Last updated 2019-02-28
Summary
Published data regarding the temporal pattern of AML are scarce and old. The greater knowledge of these neoplasias has made that their classification has been remarkable modified. Therefore, we consider relevant to carry out the present study as it would allow us to analyze the potential existence of a spatio-temporal pattern in the incidence of AML in Spain.
Conditions
Sponsors & Collaborators
-
Celgene
collaborator INDUSTRY -
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
lead OTHER
Eligibility
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-01-01
- Primary Completion
- 2019-01-15
- Completion
- 2019-01-15
Countries
- Spain
Study Locations
More Related Trials
-
Exploring Disease Immunogenicity and the Immunological Effects of Hypomethylating Agents in Acute Myeloid Leukemia
NCT03789981 ·Status: ACTIVE_NOT_RECRUITING
-
Azacitidine and Lenalidomide for Relapsed and Refractory Patients With Acute Myeloid Leukemia
NCT01743859 ·Status: COMPLETED ·Phase: PHASE2
-
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies
NCT05772559 ·Status: RECRUITING
-
NGS in AML Relapse
NCT03582241 ·Status: UNKNOWN
-
Treatment Patterns and Key Healthcare Resource Use in Acute Myeloid Leukemia (AML) With or Without FMS-like Tyrosine Kinase-3 (FLT3) Mutation Study Based on Retrospective Chart Review
NCT03047083 ·Status: COMPLETED
-
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
NCT04777916 ·Status: RECRUITING
-
Assessing Refractoriness and Infectious Survival Events in AML
NCT06709235 ·Status: COMPLETED
-
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
NCT00126321 ·Status: UNKNOWN ·Phase: PHASE2
-
Diagnostic Platform to Perform Centralized and Standardized Rapid Molecular Diagnosis by Next Generation Sequencing (NGS) in Patients Diagnosed With Acute Myeloid Leukemia.
NCT03311815 ·Status: COMPLETED
-
Study to Assess Length of Remission With Intensive Chemotherapy in Rapidly Responding AML Patients.
NCT03902769 ·Status: UNKNOWN ·Phase: NA
-
Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine
NCT01392079 ·Status: COMPLETED ·Phase: PHASE2
-
Analysis of T Cell Metabolism in Acute Myeloid Leukemia Patients
NCT04259372 ·Status: COMPLETED
-
Monitoring Minimal Residual Disease of Patients With Acute Myelogenous Leukemia or High Grade Myelodysplastic Syndrome
NCT01311258 ·Status: RECRUITING
-
Dynamics of Resistance Emergence to Azacitidine-based Therapies in Acute Myeloid Leukemia
NCT06225128 ·Status: RECRUITING
-
Clinico-hematological and Coagulation Profiles in Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Intensive Induction Chemotherapy .
NCT07343687 ·Status: NOT_YET_RECRUITING
-
Feasibility Study of Intermediate Doses of ARA-C With Autologous SCT as Consolidation of Low/Intermediate-risk AML
NCT03023384 ·Status: UNKNOWN
-
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
NCT06459024 ·Status: RECRUITING
-
Phase I AZD2171 in Patients With Relapsed or Refractory AML and Elderly Patients With DeNovo or Secondary AML
NCT00502385 ·Status: COMPLETED ·Phase: PHASE1
-
Outcomes of Acute Myeloid Leukemia Patients
NCT04392310 ·Status: UNKNOWN
-
Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways
NCT05124288 ·Status: RECRUITING
-
Prognostic Factors and the Impact of Various Management of Acute Myeloid Leukemia in Real Life Condition
NCT03284593 ·Status: ACTIVE_NOT_RECRUITING
-
All-Trans Retinoic Acid in Combination With Standard Induction and Consolidation Therapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia
NCT00151255 ·Status: COMPLETED ·Phase: PHASE3
-
Sequential Conditioning in Haploidentical Transplantation for Refractory Acute Myeloid Leukemia
NCT03035422 ·Status: COMPLETED ·Phase: NA
-
Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance
NCT02756962 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Observational Study on the Outcome of AML Patients Treated With New Drugs in Real-life (BoxTrial)
NCT06513273 ·Status: RECRUITING